BioPharmSignal logoBioPharmSignal

Biotech News

Milestone Pharmaceuticals to Announce Third Quarter 2026 Financial Results on November 13, 2026

Milestone Pharmaceuticals Inc. (MIST)Milestone Pharmaceuticals Inc.Earnings

MONTREAL and CHARLOTTE, N.C., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Milestone ® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that it will report its financial results for the

Related news

MISTMilestone Pharmaceuticals Inc.2026-08-04 20:01 EST

Milestone Pharmaceuticals to Announce Second Quarter 2026 Financial Results on August 12, 2026

MISTMilestone Pharmaceuticals Inc.2026-08-12 11:08 EST

Milestone Pharmaceuticals Announces Second Quarter 2026 Financial Results and Provides Corporate Update

LXRXLexicon Pharmaceuticals2026-10-29 12:30 EST

Lexicon Pharmaceuticals to Report Third Quarter 2026 Financial Results on November 5, 2026

RYTMRhythm Pharmaceuticals2026-10-21 12:00 EST

Rhythm Pharmaceuticals to Report Third Quarter 2026 Financial Results on Tuesday, November 3, 2026

MLYSMineralys Therapeutics2026-10-28 20:05 EST

Mineralys Therapeutics to Announce Third Quarter 2026 Financial Results and Host Conference Call on Wednesday, November 4, 2026

RYTMRhythm Pharmaceuticals2026-11-03 12:00 EST

Rhythm Pharmaceuticals Reports Third Quarter 2026 Financial Results and Business Update

ALTAltimmune2026-11-05 13:00 EST

Altimmune to Report Third Quarter 2026 Financial Results and Provide Business Update on November 12, 2026

MNKDMannKind2026-10-29 20:01 EST

MannKind to Report Third Quarter Financial Results and Host Conference Call on November 5, 2026

CVRXCVRx2026-10-22 20:30 EST

CVRx to Report Third Quarter 2026 Financial and Operating Results and Host Conference Call on November 5, 2026

LXRXLexicon Pharmaceuticals2026-08-06 11:30 EST

Lexicon Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Clinical Updates

View all latest news

Milestone Pharmaceuticals Inc.

Self-Administered Cardiac Rescue Therapy Milestone Pharmaceuticals develops rapid-onset nasal therapies for episodic cardiovascular conditions that patients can administer outside a medical setting. CARDAMYST CARDAMYST is an FDA-approved etripamil nasal spray that adults can self-administer to convert symptomatic paroxysmal...

Recent company news

MISTMilestone Pharmaceuticals Inc.2026-11-04 01:45 EST

Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

MISTMilestone Pharmaceuticals Inc.2026-11-03 13:00 EST

Milestone Pharmaceuticals to Announce Third Quarter 2026 Financial Results on November 13, 2026

MISTMilestone Pharmaceuticals Inc.2026-11-02 13:00 EST

New Data Presented at AHA Scientific Sessions 2026 Demonstrate That CARDAMYST® (etripamil) Nasal Spray Converted Recurrent PSVT to Normal Heart Rhythm in Patients with Prior Catheter Ablation

MISTMilestone Pharmaceuticals Inc.2026-10-19 12:00 EST

Milestone Pharmaceuticals Announces Clinical Data Presentations at Upcoming Cardiology Conferences

MISTMilestone Pharmaceuticals Inc.2026-10-09 12:00 EST

Milestone Pharmaceuticals Announces First European Study Participant Enrolled in ReVeRA-301 Phase 3 Clinical Trial

Stock data

Close
0.69 USD
Market cap
164.34M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States